



# Quanto Strategy Certificates

Linked to Euro High Dividend Income Basket EUR  
Issued by UBS AG Zurich



Cash settled  
SVSP Product Type: Tracker Certificates (1300\*, callable)  
Valor: 24971391; ISIN: CH0249713915

**Amendment as of 25 January 2023: Rebalancing / Adjustment Fee reduced from 0.10% to 0.05%**

**Amendment as of 13 April 2021: Extension of Expiration Date by an additional 5 years to 16 October 2026**

**Amendment as of 1 January 2017: added paragraph regarding US Withholding Tax (regulation 871m)**

## Final Terms

This Product does not represent a participation in any of the collective investment schemes pursuant to Art. 7 ff of the Swiss Federal Act on Collective Investment Schemes (CISA) and thus does not require an authorisation of the Swiss Financial Market Supervisory Authority (FINMA). Therefore, investors in this Product are not eligible for the specific investor protection under the CISA.

### 1. Description of the Product

#### Information on Underlying

The Euro High Dividend Income Basket enables the investor to participate at the net total return (capital appreciation and net dividends) of a notional actively managed reference-portfolio of shares. The strategy focuses on Euro High Dividend Income stocks rebalanced by the Reference-Portfolio Advisor.

#### Underlying(s)

#### Description

**Euro High Dividend Income Basket EUR**  
(the "Reference-Portfolio")

**Euro High Dividend Income Basket EUR** (the "Reference-Portfolio") is a notional EUR ("EUR") denominated actively managed Reference-Portfolio, created and maintained by Banque Audi (Suisse) SA (the "Reference-Portfolio Advisor"). The Reference-Portfolio aims to replicate (i) the performance of a basket of Euro High Dividend Income stocks, listed options (long), listed single stock calls (short) as long as the stock is in the portfolio, listed single stock puts (short) as long as the cash covers the position (the "Constituents") and (ii) from time to time, a cash position (the "Cash Position", which together with the Constituents shall be referred to as the "Reference-Portfolio Components"), less fees and expenses. The Reference-Portfolio Advisor maintains the Reference-Portfolio in accordance with the attached Reference-Portfolio Guidelines (Annex).

#### Product Details

Security Numbers	Valor: 24971391/ ISIN: CH0249713915/ WKN: UA52EW
Issue Size	Up to 30'000 Units (with reopening clause) (Issue Size decreased by 270,000 Units on VD 18 March 2021)
Issue Price	EUR 100.00 (Unit Quotation)
Settlement Currency	EUR
Currency Treatment	The Reference-Portfolio can invest in and be exposed to Reference-Portfolio Components denominated in currencies other than the Settlement Currency. <b>The currency risk is hedged into EUR</b>

**Contact:** UBS AG, P.O. Box, 8098 Zurich

Institutional Investors: 41-44-239 14 66\*  
Private Investors: [derivatives@ubs.com](mailto:derivatives@ubs.com)

Internet: [www.ubs.com/keyinvest](http://www.ubs.com/keyinvest)

Please note that calls made to the numbers marked with an asterisk (\*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

## Dates

Launch Date	16 October 2014
Pricing Date ("Pricing")	16 October 2014
Issue Date / Payment Date	23 October 2014
Last Trading Day	16 October 2026
Expiration Date	16 October 2026 (subject to Market Disruption Events, Early Termination and Unwind Disruption provisions), extendable at the option of the Issuer for additional 5 years periods, on a rolling basis, with a notice period of 180 calendar days. In case of an extension, an Investor can with a notice period of 90 days prior to the Expiration Date request from the Issuer in writing that his Products are redeemed at the Redemption Date following the original Expiration Date. In case this is not a Business Day, the next following Business day will apply. For the avoidance of doubt: Such request of redemption shall be possible after each extension of the term.
Redemption Date	5 Business Days following the Expiration Date (currently expected to be 23 October 2026) or the Early Termination Date (as applicable) (in any case subject to Market Disruption Event provisions).

## Redemption

Redemption Amount The Investor is entitled to receive from the Issuer on the Redemption Date an amount in the Settlement Currency equal to the Reference-Portfolio Level on the Expiration Date or the Early Termination Date, as applicable, as calculated by the Calculation Agent.

In the event that a notional investor (in the same position as the Issuer) would be unable to unwind its investments in any of the Reference-Portfolio Components by the Expiration Date or the Early Termination Date (as applicable) (such event a "**Unwind Disruption**"), the Issuer reserves the right to extend the Expiration Date or Early Termination Date to such date where a notional investor in the Reference-Portfolio Components is able to fully unwind the Reference-Portfolio Components in cash.

For the avoidance of doubt, the Redemption Amount in case of an Early Termination may include (inter alia) any costs arising from the Issuer unwinding any hedges in connection with the Product.

**Please note that the Redemption Amount may be less than the initially invested capital.**

Special Performance Distribution From time to time the Reference Portfolio Advisor may decide in its own discretion to conduct a Special Performance Distribution payment to each Investor in order to distribute part or all of the gains on Constituents accrued since (i) Issue Date or (ii) since the last Special Performance Distribution, as applicable. Such payment will reduce the Reference-Portfolio Level by the exact same amount that is paid to the Investors via the clearing systems.

Early Termination by Issuer The Issuer is entitled to early terminate the Product in full subject to the following notice period:

Quarterly, i.e. as of each 30 June, 30 September, 31 December, 31 March (the "**Early Termination Date**") subject to at least 45 Business Days prior notice being given to the Investors. The first possible Early Redemption Date will be 31 December 2014.

Should Banque Audi cease to be the Reference-Portfolio Advisor, the Products will be early terminated by the Issuer as of the first Early Termination Date on which Banque Audi no longer acts as the Reference-Portfolio Advisor, as determined at the reasonable discretion of the Calculation Agent. No notice period shall apply in that case.

**There is no Early Termination right for the Investor.**

**Contact:** UBS AG, P.O. Box, 8098 Zurich  
Institutional Investors: +41-44-239 77 60\*  
Private Investors: [derivatives@ubs.com](mailto:derivatives@ubs.com) Internet: [www.ubs.com/keyinvest](http://www.ubs.com/keyinvest)

Please note that calls made to the numbers marked with an asterisk (\*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

Reference-Portfolio Level	Sum of all Reference-Portfolio Constituents taking into consideration their respective weightings, plus the Cash Position, whereby a Constituent is valued at the closing price published by the primary exchange of the respective stock or option, all converted into the Settlement Currency at the respective WMCO exchange rate (4.00 p.m. London Time). The calculation also takes into account the effect of all fees and costs associated with the Reference-Portfolio through reduction in the Number of Reference-Portfolio Components referenced by each Reference-Portfolio Unit as determined by the Calculation Agent action in good faith and in a commercially reasonable manner. The Reference-Portfolio Level is calculated for each Business Day by the Calculation Agent on the next Business Day. No interest will be paid on the Cash Position.
Dividends	<p>Dividend Payments on Constituents are taken into account on the corresponding Dividend Ex-Date within the Cash Position at the value of the distribution (net of any taxes, costs and expenses, as determined by the Calculation Agent for each Constituent). From time to time the Reference Portfolio Advisor may decide in its own discretion to pay out some or all of the Dividends accrued since the Issue Date.</p> <p>In respect of U.S. equity securities, for purposes of determining the amount of a dividend treated as notionally reinvested, such amount shall not be treated as reduced by the withholding tax imposed on dividends by Section 871(a) or 881(a) of the US Internal Revenue Code but shall instead be reduced by the 30% withholding tax imposed on dividend equivalents by Section 871(m) of the U.S. Internal Revenue Code of 1986, as amended.</p>

## Product Structure

The Product allows for participation in the performance of the Reference-Portfolio Constituents plus net Dividends. The Reference-Portfolio is a notional actively managed portfolio based on a basket of stocks, options and Cash, maintained by the Reference-Portfolio Advisor according to the attached Reference-Portfolio Guidelines. The Reference-Portfolio aims to replicate the performance level of a basket of stocks, options and, from time to time a cash position, less fees, costs and expenses. Any amounts reflecting net dividends of the Reference-Portfolio Constituents will held in cash in the Settlement Currency and may be distributed to Investors from time to time.

## General Information

Issuer	UBS AG, Zurich
Issuer Rating	A2 Moody's / A S&P's / A Fitch
Lead Manager	UBS AG, Zurich (UBS Investment Bank)
Calculation Agent	UBS AG, London Branch
Paying Agent	UBS AG, Zurich
Reference-Portfolio Advisor	Banque Audi (Suisse) SA, which is authorised and regulated by the Swiss Financial Market Supervisory Authority (FINMA)
Business Days	Any days in which banks in London, Frankfurt a.M., Zurich, Hong Kong and New York are open for business.
Listing	No Listing
Liquidity	UBS intends to offer daily bid/offer prices depending on size, market conditions such as liquidity in the markets of the Reference-Portfolio Components.
Reference-Portfolio fees (calculated daily)	Quarterly fee of 0.275% (1.10% per year) of the Reference-Portfolio Level accrued on a daily basis, plus (i) certain expenses commonly to be associated with establishing, maintaining and rebalancing a portfolio similar to the notional portfolio mirrored by the Reference-Portfolio and (ii) the Adjustment Fee, charged by the Calculation Agent and deducted from the Reference-Portfolio Level. The dates of the 0.275% fee deduction are 30 March, 30 June, 30 September and 31 December (in case any of the dates is not a Business Day, the next following Business Day will apply). <b>A part of the Reference-Portfolio Fee will be used to compensate the Reference Portfolio Advisor.</b>

**Contact:** UBS AG, P.O. Box, 8098 Zurich  
Institutional Investors: +41-44-239 77 60\*  
Private Investors: [derivatives@ubs.com](mailto:derivatives@ubs.com) Internet: [www.ubs.com/keyinvest](http://www.ubs.com/keyinvest)

Please note that calls made to the numbers marked with an asterisk (\*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

Quanto Fees	A quarterly fee of 0.0375% (0.15% per year) will apply of the Reference-Portfolio Level, accrued on a daily basis. The dates of the Quanto Fee deduction are 31 March, 30 June, 30 September and 31 December (in case any of the dates is not a Business Day, the next following Business Day will apply). Should the costs for Quanto hedging exceed 0.0375% per quarter, the Issuer reserves its right to increase the Quanto Fees with immediate effect to such level that reflects the increased costs, as determined by the Calculation Agent action in good faith and in a commercially reasonable manner, by giving notice to the Investors to such extent.
Rebalancing	<p>Rebalancing means any change in the composition or weighting of the Reference-Portfolio Components by the Reference-Portfolio Advisor after the Issue Date. The Calculation Agent has the right to reject Rebalancings under specific circumstances. The expected number of Rebalancings per year is 52.</p> <p>In case of a Rebalancing, secondary market trading of the Product may be suspended until completion of the Rebalancing.</p>
Rebalancing / Adjustment Fee	An Adjustment Fee is levied for each adjustment made in the Reference-Portfolio, and represents a percentage of the notional volume of each of the purchase and/or sale of a Constituent. The Adjustment equals 0.05% as at the Launch Date.
Adjustment	The Adjustment Fee can be adjusted by the Reference-Portfolio Calculation Agent, but may not amount to more than 0.25%.
Minimum Investment	1 Unit(s)
Minimum Trading Lot	1 Unit(s)
Clearing	SIX SIS, Euroclear, Clearstream (registered as intermediated securities with SIX SIS AG, in Switzerland)
Form of deed	Uncertificated Securitates
Governing Law / Jurisdiction	Switzerland / Zurich
Adjustments	The terms of the Product may be subject to adjustments during its lifetime. Detailed information on such adjustments is to be found in the Product Documentation.
Public Offering	Switzerland

### **Tax Treatment Switzerland**

---

Swiss Federal Stamp Duty	The product is not subject to Swiss Federal Stamp Duty.
Swiss Federal Income Tax	The taxable income and capital gains/losses will be kept apart and will be reported to the Swiss Federal Tax Administration annually. Taxable income is subject to Swiss Federal, cantonal and communal income tax.
Swiss Withholding Tax	The product is not subject to the Swiss withholding tax.
EU Savings Tax Treatment	For Swiss paying agents, the product is not subject to the EU Savings tax.

The tax information only provides a general overview of the potential tax consequences linked to this product at the time of issue. Tax laws and tax doctrine may change, possibly with retroactive effect.

**Contact:** UBS AG, P.O. Box, 8098 Zurich  
Institutional Investors: +41-44-239 77 60\*  
Private Investors: [derivatives@ubs.com](mailto:derivatives@ubs.com) Internet: [www.ubs.com/keyinvest](http://www.ubs.com/keyinvest)

Please note that calls made to the numbers marked with an asterisk (\*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

## Product Documentation

---

This document ("Final Terms") constitutes the Simplified Prospectus for the Product and contains the information required by Article 5 CISA and the corresponding Guidelines of the Swiss Bankers Association. The prospectus requirements of Article 652a/ Article 1156 of the Swiss Code of Obligations are not applicable. These Final Terms (Simplified Prospectus) together with the 'General Terms and Conditions for Structured Products on Equity, Commodity and Index Underlyings', stipulated in English and as amended from time to time ("General Terms and Conditions") shall form the entire documentation for this Product ("Product Documentation"), and accordingly the Final Terms should always be read together with the General Terms and Conditions. The Simplified Prospectus may be provided in various languages, however, only the English version will be relevant and any translations are for convenience only. Definitions used in the Final Terms, but not defined therein shall have the meaning given to them in the General Terms and Conditions. In the event that the Product is listed (see above item 'Listing' under «General Information»), the Product Documentation will be amended in accordance with the listing requirements of the relevant exchange. The Product Documentation can be obtained free of charge from UBS AG, P.O. Box, CH-8098 Zurich (Switzerland), via telephone (+41-(0)44-239 47 03), fax (+41-(0)44-239 69 14) or via e-mail (swiss-prospectus@ubs.com). In addition, for clients outside of the United Kingdom, the Product Documentation is available on the internet at [www.ubs.com/keyinvest](http://www.ubs.com/keyinvest). Notices in connection with this Product shall be validly given by publication as described in the General Terms and Conditions. Furthermore, for clients outside of the United Kingdom, any changes with regard to the terms of this Product shall be published on the internet at [www.ubs.com/keyinvest](http://www.ubs.com/keyinvest).

## Classification

---

This Product does not represent a participation in any of the collective investment schemes pursuant to Art. 7 ff of the Swiss Federal Act on Collective Investment Schemes (CISA) and thus does not require an authorisation of the Swiss Financial Market Supervisory Authority (FINMA). Therefore, investors in this Product are not eligible for the specific investor protection under the CISA.

Furthermore, this Product does not benefit from any depositor protection under Art. 37b under the Swiss Federal Law on Banks and Savings Banks (Banking Act) or other forms of deposit insurance under any other law as might be applicable to this Product.

## Prudential Supervision

---

UBS AG is authorised and regulated by the Swiss Financial Market Supervisory Authority (FINMA). In addition, its London Branch is authorised and regulated by the Financial Services Authority (FSA) and its Jersey Branch by the Jersey Financial Services Commission (JFSC).

## 2. Prospects of Profits and Losses

Market Expectation	Investor expects the positive performance in a basket of stocks and options, which is actively managed by the Reference-Portfolio Advisor, over the life of the Product.
Risk Tolerance	Investors should be familiar with stock markets investments, options and the asset management abilities of the Reference-Portfolio Advisor. The investors must be willing to make an investment that is fully exposed to the performance of the Underlying, which is actively managed by the Reference-Portfolio Advisor, meaning that investors might lose their whole investment in the Product in the worst case. The Reference-Portfolio may contain Reference-Portfolio Components denominated in currencies other than the Settlement Currency. The currency risk is hedged.

**Contact:** UBS AG, P.O. Box, 8098 Zurich  
Institutional Investors: +41-44-239 77 60\*  
Private Investors: [derivatives@ubs.com](mailto:derivatives@ubs.com) Internet: [www.ubs.com/keyinvest](http://www.ubs.com/keyinvest)

Please note that calls made to the numbers marked with an asterisk (\*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

Profit Potential	<p>The Product allows for participation in positive performance of the Underlying, as adjusted by various fees and expenses as described in more detail above.</p> <p>Furthermore, if prior to the Expiration Date the Investor decides to buy/sell the Product under the Secondary Market terms (as detailed above), the Investor may also be exposed to any funding costs of the Issuer (including, but not limited to, any internal funding costs whether caused by changes in UBS's credit status or otherwise) in relation to the Product.</p>
Loss Potential	<p>The Investors may lose some or all of the investment as they are fully exposed to the negative performance of the Underlying.</p> <p>The Issuer is entitled to redeem the Product early.</p>

### 3. Significant Risks for Investors

**For product specific risks please see above (2. Prospects of Profits and Losses)**

#### Risk Factors relating to the Issuer

---

In addition to the market risk with regard to the development of the Underlying, each Investor bears the general risk that the financial situation of the Issuer could deteriorate. The Products constitute immediate, unsecured and unsubordinated obligations of the Issuer, which, particularly in case of insolvency of the Issuer, rank pari passu with each and all other current and future unsecured and unsubordinated obligations of the Issuer, with the exception of those that have priority due to mandatory statutory provisions. The general assessment of the Issuer's creditworthiness may affect the value of the Products. This assessment generally depends on the ratings assigned to the Issuer or its affiliated companies by rating agencies such as Moody's, Fitch and Standard & Poor's.

The Issuer Ratings indicated in this document reflect the situation at the time of issuance and may be subject to changes. The actual Issuer Ratings at any given time can be seen on the Issuer's website ([www.ubs.com](http://www.ubs.com)) under "Analysts & Investors".

#### Secondary Market

---

The Issuer or the Lead Manager, as applicable, intends, under normal market conditions, to provide bid and offer prices for this Product on a regular basis. However, the Issuer or the Lead Manager, as applicable, makes no firm commitment to provide liquidity by means of bid and offer prices for this Product, and assumes no legal obligation to quote any such prices or with respect to the level or determination of such prices. Potential Investors therefore should not rely on the ability to sell this Product at a specific time or at a specific price.

In special market situations, where the Issuer is completely unable to enter into hedging transactions, or where such transactions are very difficult to enter into, the spread between the bid and offer prices may be temporarily expanded, in order to limit the economic risks of the Issuer.

#### Market Risk

---

The investor is exposed to market disruption events (such as trading disruption, exchange disruption and early closure of the relevant exchange), adjustments and early termination which could have an impact on the redemption amount through delay in payment or change in value. For a detailed description of such events and their effects please read the Final Terms and the base prospectus (Base Prospectus Equity).

**Contact:** UBS AG, P.O. Box, 8098 Zurich  
Institutional Investors: +41-44-239 77 60\*  
Private Investors: [derivatives@ubs.com](mailto:derivatives@ubs.com) Internet: [www.ubs.com/keyinvest](http://www.ubs.com/keyinvest)

Please note that calls made to the numbers marked with an asterisk (\*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

## Important Information

---

This information is communicated by UBS AG and/or its affiliates ("UBS"). UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the transaction to which this document relates. UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this document. UBS' trading and/or hedging activities related to this transaction may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier is crossed. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available.

In certain circumstances UBS sells this Product to dealers and other financial institutions at a discount to the issue price or rebates to them for their account some proportion of the issue price. Further information is available on request.

Structured transactions are complex and may involve a high risk of loss. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in any transaction.

This document should not be construed as an offer, personal recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice. The terms of any investment will be exclusively subject to the detailed provisions, including risk considerations, contained in the Information Memorandum, Prospectus or other issuer documentation for the issue of the Products/Notes (the "Prospectus").

UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This document shall not be copied or reproduced without UBS' prior written permission.

No action has been or will be taken in any jurisdiction that would permit a public offering of the Products described herein, save where explicitly stated in the Product Documentation. The Products must be sold in accordance with all applicable selling restrictions in the jurisdictions in which they are sold.

There is a possibility that costs, including taxes, related to transactions in connection with this Product may arise for the Investor that are not paid by UBS or imposed by it.

**Contact:** UBS AG, P.O. Box, 8098 Zurich  
Institutional Investors: +41-44-239 77 60\*  
Private Investors: [derivatives@ubs.com](mailto:derivatives@ubs.com) Internet: [www.ubs.com/keyinvest](http://www.ubs.com/keyinvest)

Please note that calls made to the numbers marked with an asterisk (\*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

## Selling Restrictions

**Any Products purchased by any person for resale may not be offered in any jurisdiction in circumstances which would result in the Issuer being obliged to register any further documentation relating to this Product in such jurisdiction.**

**The restrictions listed below must not be taken as definitive guidance as to whether this Product can be sold in a jurisdiction. Additional restrictions on offering, selling or holding of this Product may apply in other jurisdictions. Investors in this Product should seek specific advice before on-selling this Product.**

**Europe** - Any public offer of this Product within a EEA jurisdiction (EU member states plus Norway, Iceland and Liechtenstein) shall only be possible if compliant with the requirements of the EUPD and with the law of that jurisdiction.

If the prospectus either does not qualify as a prospectus published in accordance with the requirements of the EUPD or is not filed with or notified to the relevant Financial Supervisory Authority, this Product may not be offered or sold in EEA jurisdictions other than 1) in minimum denominations of, or total consideration per investor of at least, EUR 50,000 (or equivalent in other currencies), provided that the offer is only being made in one or more EEA jurisdiction that will not, before the end of the offer period for the Notes, have implemented the provision under the Directive 2010/73/EU (the "PD Amending Directive") that increase this minimum denomination (or total consideration per investor) to EUR 100,000; or 2) only to Qualified Investors; and/or (aggregated for all distributors) to less than 100 or, if the relevant EEA jurisdiction has implemented the relevant provision of the 2010 PD Amending Directive, 150 natural or legal persons that are not Qualified Investors per EEA jurisdiction. "Qualified Investors" are persons or entities as defined in the Prospectus Directive.

For information on public offering in EEA jurisdictions please see under section "General Information" above.

**Hong Kong** – Each purchaser has represented and agreed that it has not issued or had in its possession for the purposes of issue, and will not issue or have in its possession for the purposes of issue, whether in Hong Kong or elsewhere, any advertisement, invitation or document relating to the Products, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to Products which are or are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance.

**This is a structured product which involves derivatives. Do not invest in it unless you fully understand and are willing to assume the risks associated with it. If you are in any doubt about the risks involved in the product, you may clarify with the intermediary or seek independent professional advice.**

Singapore - This Term Sheet, the Final Terms, the Base Prospectus and the Supplemental Prospectus in respect of the programme under which the Notes would be issued have not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this Term Sheet, the Final Terms, the Base Prospectus, the Supplemental Prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the Notes may not be circulated or distributed, nor may the Notes be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA"), (ii) to a relevant person pursuant to Section 275(1), or any person pursuant to Section 275(1A), and in accordance with the conditions specified in Section 275, of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

Where the Notes are subscribed or purchased under Section 275 of the SFA by a relevant person which is:

(a) a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or  
(b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor,  
securities (as defined in Section 239(1) of the SFA) of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the Notes pursuant to an offer made under Section 275 of the SFA except:

(1) to an institutional investor or to a relevant person defined in Section 275(2) of the SFA, or to any person arising from an offer referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA;  
(2) where no consideration is or will be given for the transfer;  
(3) where the transfer is by operation of law;  
(4) as specified in Section 276(7) of the SFA; or  
(5) as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore.

**UK** – For the purpose of non-discretionary accounts, this Product should not be sold with a consideration of less than 100,000 EUR or equivalent.

**USA** - This Product may not be sold or offered within the United States or to U.S. persons.

**Contact:** UBS AG, P.O. Box, 8098 Zurich  
Institutional Investors: +41-44-239 77 60\*  
Private Investors: [derivatives@ubs.com](mailto:derivatives@ubs.com) Internet: [www.ubs.com/keyinvest](http://www.ubs.com/keyinvest)

Please note that calls made to the numbers marked with an asterisk (\*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.



## Annex

### Reference-Portfolio Guidelines

#### Euro High Dividend Income Basket EUR

**Euro High Dividend Income Basket EUR (the "Reference-Portfolio") is a notional EUR ("EUR") denominated actively managed Reference-Portfolio, created and maintained by Banque Audi (Suisse) SA (the "Reference-Portfolio Advisor"). The Reference-Portfolio aims to replicate (i) the performance of a basket of Euro High Dividend Income stocks, listed options (long), listed single stock calls (short) as long as the stock is in the portfolio, listed single stock puts (short) as long as the cash covers the position (the "Constituents") and (ii) from time to time, a cash position (the "Cash Position", which together with the Constituents shall be referred to as the "Reference-Portfolio Components"), less fees and expenses. The Reference-Portfolio Advisor maintains the Reference-Portfolio in accordance with the attached Reference-Portfolio Guidelines::**

1. Only shares with sufficient liquidity which are at the time of the relevant Rebalancing a constituent of an Eligible Index (see below) may be incorporated as Reference-Portfolio Constituents in the Reference-Portfolio ("Eligible Stocks"). "Eligible Indices" means the following indices identified by their Bloomberg Ticker:

MSCI World Index. *Bloomberg: MXWO Index*

Listed Single Stock Options (Long) with a maturity > 1 month

Listed Single Stock Calls (Short) as long as the stock is in the portfolio with a maturity > 1 month

Listed Single Stock Puts (Short) as long as the cash covers the position in the portfolio with a maturity > 1 month

2. The Cash Position may at no time exceed 50% of the value of the Reference-Portfolio two months after the launch of the product. No interest will be paid on the Cash Position.

In case of a rebalancing the theoretical volume of a buy or sell order for a Constituent is limited to 200% of the average traded daily volume of that Constituent. A rebalancing may happen at the discretion of the Reference-Portfolio Advisor. The Calculation Agent has the right to reject Constituents that form part of a Rebalancing. The theoretical volume is defined as the number of outstanding Units multiplied by the Reference-Portfolio Level (using a reasonable foreign exchange rate to convert into the currency of the Constituent) and multiplied by the change in the percentage weight of the Constituent. The average traded daily volume is defined as the 30 Day average trading turnover. The expected number of Rebalancings per year is 52.

At any time, the Reference-Portfolio may reflect a cash position which mirrors the holding of cash or money market instruments (the "Cash Position").

A Quarterly fee of 0.275% (1.10% per year) of the Reference-Portfolio Level accrued on a daily basis, plus (i) certain expenses commonly to be associated with establishing, maintaining and rebalancing a portfolio similar to the notional portfolio mirrored by the Reference-Portfolio and (ii) the Adjustment Fee, charged by the Calculation Agent and deducted from the Reference-Portfolio Level. The dates of the 0.275% fee deduction are 31 March, 30 June, 30 September and 31 December (in case any of the dates is not a Business Day, the next following Business Day will apply). A part of the Reference-Portfolio Fee will be used to compensate the Reference Portfolio Advisor.

An Adjustment Fee is levied for each adjustment made in the Reference-Portfolio, and represents a percentage of the notional volume of each of the purchase and/or sale of an Eligible Stock. The Adjustment Fee was set by the Reference-Portfolio Advisor in accordance with the Reference-Portfolio Calculation Agent at 0.05% as at the Launch Date. The Reference-Portfolio Fee is accrued on a daily basis and paid on a quarterly basis, on 31 March, 30 June, 30 September and 31 December should any of these dates fall on a day which is not a Business Day, the Fee is paid on the next Business Day).

The Reference-Portfolio is denominated in EUR, while the Constituents, notionally comprised in the Reference-Portfolio, might be denominated in other currencies than EUR

In order to appropriately reflect the performance of the Constituents in the determination of the value of the Reference-Portfolio, the value of the Constituents denominated in other currencies than EUR is expressed in EUR. The currency risk is hedged into EUR (quanto).

A quarterly Quanto Fee of 0.0375% (0.15% per year) will apply of the Reference-Portfolio Level, accrued on a daily basis. The dates of the Quanto Fee deduction are 31 March, 30 June, 30 September and 31 December (in case any of the dates is not a Business Day, the next following Business Day will apply). Should the costs for Quanto hedging exceed 0.0375% per quarter, the Issuer reserves its right to increase the Quanto Fees with immediate effect to such level that reflects the increased costs, as determined by the Calculation Agent action in good faith and in a commercially reasonable manner, by giving notice to the Investors to such extent.

The above Universe can be amended in agreement between the Calculation Agent and the Reference-Portfolio Advisor. The Calculation Agent has the right to reject Constituents that form part of a Rebalancing.

**Contact:** UBS AG, P.O. Box, 8098 Zurich  
Institutional Investors: +41-44-239 77 60\*  
Private Investors: [derivatives@ubs.com](mailto:derivatives@ubs.com) Internet: [www.ubs.com/keyinvest](http://www.ubs.com/keyinvest)

Please note that calls made to the numbers marked with an asterisk (\*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

The initial number of Constituents will be 24. The initial positions are:

Ticker	Company Name
-	Cash
SAN SM Equity	BANCO SANTANDER SA
GIMB BB Equity	GIMV NV
ENI IM Equity	ENI SPA
ECMPA NA Equity	EUROCOMMERCIAL PROPERTIE-CV
ENG SM Equity	ENAGAS SA
SRG IM Equity	SNAM SPA
VOD LN Equity	VODAFONE GROUP PLC
SSE LN Equity	SSE PLC
GSK LN Equity	GLAXOSMITHKLINE PLC
HSBA LN Equity	HSBC HOLDINGS PLC
NG/ LN Equity	NATIONAL GRID PLC
BA/ LN Equity	BAE SYSTEMS PLC
IMT LN EQUITY	IMPERIAL TOBACCO GROUP PLC
RDSA LN Equity	ROYAL DUTCH SHELL PLC-A SHS
BP/ LN Equity	BP PLC
PERSON LN Equity	PEARSON PLC
AZN LN Equity	ASTRAZENECA PLC
TEL NO Equity	TELENOR ASA
ZURN VX Equity	ZURICH INSURANCE GROUP AG
FP FP Equity	TOTAL SA
ALV GY Equity	ALLIANZ SE-REG
ATL IM Equity	ATLANTIA SPA
TLSN SS Equity	TELIASONERA AB
TRN IM Equity	TERNA SPA

**Contact:** UBS AG, P.O. Box, 8098 Zurich

Institutional Investors: +41-44-239 77 60\*  
Private Investors: [derivatives@ubs.com](mailto:derivatives@ubs.com)

Internet: [www.ubs.com/keyinvest](http://www.ubs.com/keyinvest)

Please note that calls made to the numbers marked with an asterisk (\*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.